Transforming type 1 diabetes: the next wave of innovation
- 6 February 2021
- journal article
- review article
- Published by Springer Nature in Diabetologia
- Vol. 64 (5) , 1059-1065
Abstract
The discovery of insulin in 1921 enabled pharmaceutical production of animal insulins for the treatment of people with type 1 diabetes by 1922. The last several decades have witnessed enormous scientific progress in the therapy of type 1 diabetes, yet some developments have been incremental, and insulin is not a cure. Herein, I highlight key scientific advances potentially poised to improve the quality of life and treatment outcomes in type 1 diabetes. These innovations range from newer insulin analogues to the development of smart insulins, oral and weekly insulins, glucose sensors and closed-loop insulin-delivery devices, as well as strategies for durable human beta cell replacement coupled with selective immune manipulation to preserve beta cell function. Finally, progress in the prediction and prevention of type 1 diabetes highlights the ongoing challenges and potential for altering the natural history of the disease or eliminating type 1 diabetes altogether. Graphical abstractKeywords
This publication has 24 references indexed in Scilit:
- ‘Smart’ insulin-delivery technologies and intrinsic glucose-responsive insulin analoguesDiabetologia, 2021
- The consequences of hypoglycaemiaDiabetologia, 2021
- New closed-loop insulin systemsDiabetologia, 2021
- Realising the long-term promise of insulin therapy: the DCCT/EDIC studyDiabetologia, 2021
- Once-Weekly Insulin for Type 2 Diabetes without Previous Insulin TreatmentNew England Journal of Medicine, 2020
- Risk of hypoglycaemia with insulin degludec versus insulin glargine U300 in insulin-treated patients with type 2 diabetes: the randomised, head-to-head CONCLUDE trialDiabetologia, 2020
- Advances in oral peptide therapeuticsNature Reviews Drug Discovery, 2019
- Hypoglycaemia is reduced with use of inhaled Technosphere® Insulin relative to insulin aspart in type 1 diabetes mellitusDiabetic Medicine, 2019
- Efficacy and safety of oral basal insulin versus subcutaneous insulin glargine in type 2 diabetes: a randomised, double-blind, phase 2 trialThe Lancet Diabetes & Endocrinology, 2019
- An ingestible self-orienting system for oral delivery of macromoleculesScience, 2019